Generic Drug Firms Look To Bulk Up With Addition Of Merck KGaA's Generics Unit
This article was originally published in PharmAsia News
Ranbaxy and Actavis are two potential bidders vying for Merck KGaA's generics drug unit, an acquisition that would solidify either company as the third largest generics drug maker in the world
You may also be interested in...
Company believes the acquisition will allow for creation of a controlled-release products “center of excellence.”
Hurdles for completing the acquisition still exist for Barr, which must acquire majority of Pliva shares.
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).